Doxorubicin-induced cardiac neurotoxicity: Study with iodine 123-labeled metaiodobenzylguanidine scintigraphy

Lekakis, John; Prassopoulos, Vassilios; Athanassiadis, Peter; Kostamis, P.; Moulopoulos, Spyridon D.

doi:10.1016/s1071-3581(96)90022-7

Cited by 39 publications

(23 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…37 Abnormal 123 I-MIBG uptake occurs in patients receiving anthracyclines, 38 with significantly lower H/P ratios observed with higher cumulative anthracycline dose (Figure 3). 39,40 Although a drop in H/P ratio among those receiving higher cumulative doses precedes a drop in LVEF, abnormal uptake in patients receiving low-to-medium anthracyclines also occurs. 40 This may be a promising method to detect early anthracycline injury; however, further studies are needed to quantify what interval decrease in uptake portends excessive risk of future LV dysfunction with or without continued treatment, and whether this method is applicable at lower cumulative doses.…”

Section: Radionuclide Imagingmentioning

confidence: 99%

Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs

Jiji

Kramer

Salerno

2012

Journal of Nuclear Cardiology

View full text Add to dashboard Cite

Cardiotoxicity due to administration of cancer therapeutic agents such as anthracyclines and herceptin are well described. Established guidelines to screen for chemotherapy-related cardiotoxicity (CRC) are primarily based on serial assessment of left ventricular (LV) ejection fraction (EF). However, other parameters such as LV volume, diastolic function, and strain may also be useful in screening for cardiotoxicity. More recent advances in molecular imaging of apoptosis and tissue characterization by cardiac MRI are techniques which might allow early detection of patients at high risk for developing cardiotoxicity prior to a drop in EF. This comprehensive multi-modality review will discuss both the current established imaging techniques as well as the emerging technologies which may revolutionize the future of screening and evaluation for CRC.

show abstract

Section: Radionuclide Imagingmentioning

confidence: 99%

Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs

Jiji

Kramer

Salerno

2012

Journal of Nuclear Cardiology

View full text Add to dashboard Cite

show abstract

“…The extravesicular concentration of 123 I-MIBG decreases rapidly, whereas the in-travesicular concentration remains relatively constant. The concentration plateaus after 4 h, indicating the adrenergic neuron terminal concentration (82). Therefore, the 123 I-MIBG uptake at 4 h after injection is used to explore specific neuron injury and impairment of the norepinephrine uptake function.…”

Section: I-labeled Mibg Scintigraphymentioning

confidence: 99%

Scintigraphic Techniques for Early Detection of Cancer Treatment–Induced Cardiotoxicity

et al. 2011

View full text Add to dashboard Cite

New antitumor agents have resulted in significant survival benefits for cancer patients. However, several agents may have serious cardiovascular side effects. Left ventricular ejection fraction measurement by 99m Tc multigated radionuclide angiography is regarded as the gold standard to measure cardiotoxicity in adult patients. It identifies left ventricular dysfunction with high reproducibility and low interobserver variability. A decrease in left ventricular ejection fraction, however, is a relatively late manifestation of myocardial damage. Nuclear cardiologic techniques that visualize pathophysiologic processes at the tissue level could detect myocardial injury at an earlier stage. These techniques may give the opportunity for timely intervention to prevent further damage and could provide insights into the mechanisms and pathophysiology of cardiotoxicity caused by anticancer agents. This review provides an overview of past, current, and promising newly developed radiopharmaceuticals and describes the role and recent advances of scintigraphic techniques to measure cardiotoxicity. Both first-order functional imaging techniques (visualizing mechanical [pump] function), such as 99m Tc multigated radionuclide angiography and 99m Tc gated blood-pool SPECT, and third-order functional imaging techniques (visualizing pathophysiologic and neurophysiologic processes at the tissue level) are discussed. Third-order functional imaging techniques comprise 123 I-metaiodobenzylguanidine scintigraphy, which images the efferent sympathetic nervous innervations; sympathetic neuronal PET, with its wide range of tracers; 111 In-antimyosin, which is a specific marker for myocardial cell injury and necrosis; 99m Tc-annexin V scintigraphy, which visualizes apoptosis and cell death; fatty-acid-use scintigraphy, which visualizes the storage of free fatty acids in the lipid pool of the cytosol (which can be impaired by cardiotoxic agents); and 111 In-trastuzumab imaging, to study trastuzumab targeting to the myocardium. To define the prognostic importance and clinical value of each of these functional imaging techniques, prospective clinical trials are warranted.

show abstract

“…resulting in increased competitive inhibition at the reuptake transport protein site (Lekakis et al, 1996;Higuchi & Schwaiger, 2006) and 4) direct irreversible adrenergic neuron damage (Wakasugi et al, 1993;Gupta & Amanullah, 2014). resulting in increased competitive inhibition at the reuptake transport protein site (Lekakis et al, 1996;Higuchi & Schwaiger, 2006) and 4) direct irreversible adrenergic neuron damage (Wakasugi et al, 1993;Gupta & Amanullah, 2014).…”

Section: Variablementioning

confidence: 99%

¹²³I‐MIBG imaging for detection of anthracycline‐induced cardiomyopathy

Laursen

Thune

Hutchings

et al. 2017

Clin Physio Funct Imaging

View full text Add to dashboard Cite

Due to improvements in early detection and treatment of malignant disease, the population of cancer survivors is constantly expanding. Cancer survivors are faced with chemotherapy-related long-term side effects, including irreversible cardiac injury with risk of heart failure (HF). Numerous antineoplastic regimens are associated with risk of cardiac side effects, but anthracyclines in particular carry a severe risk of cardiotoxicity. Currently, serial echocardiographic evaluation of resting left ventricular ejection fraction (LVEF) is the gold standard for monitoring anthracycline-induced cardiac side effects from chemotherapy. LVEF measurements are, however, limited by their low sensitivity. A normal LVEF does not exclude cardiotoxicity and declines in LVEF are usually not observed before the occurrence of irreversible cardiomyopathy. Hence, a clinically applicable high-sensitivity diagnostic tool for early detection of chemotherapy-related cardiotoxicity is still lacking and alternative non-invasive imaging modalities are therefore being investigated. I-MIBG is a noradrenaline (NA) analogue used for evaluation of cardiac adrenergic function, including assessment of HF prognosis and evaluation of HF treatment response. However, the role of I-MIBG for monitoring chemotherapy-related cardiotoxicity is still unclear. Here, we review the value of I-MIBG imaging for early detection and prevention of anthracycline-induced cardiomyopathy.

show abstract

Doxorubicin-induced cardiac neurotoxicity: Study with iodine 123-labeled metaiodobenzylguanidine scintigraphy

Abstract: 123I-MIBG cardiac uptake decreases in a doxorubicin dose-dependent way, indicating a cardiac adrenergic neurotoxic effect of doxorubicin. This phenomenon appears early and generally before deterioration of the ejection fraction.

Cited by 39 publications

References 12 publications

Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs

Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs

Scintigraphic Techniques for Early Detection of Cancer Treatment–Induced Cardiotoxicity

¹²³I‐MIBG imaging for detection of anthracycline‐induced cardiomyopathy

Contact Info

Product

Resources

About

Doxorubicin-induced cardiac neurotoxicity: Study with iodine 123-labeled metaiodobenzylguanidine scintigraphy

Abstract: 123I-MIBG cardiac uptake decreases in a doxorubicin dose-dependent way, indicating a cardiac adrenergic neurotoxic effect of doxorubicin. This phenomenon appears early and generally before deterioration of the ejection fraction.

Cited by 39 publications

References 12 publications

Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs

Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs

Scintigraphic Techniques for Early Detection of Cancer Treatment–Induced Cardiotoxicity

123I‐MIBG imaging for detection of anthracycline‐induced cardiomyopathy

Contact Info

Product

Resources

About

¹²³I‐MIBG imaging for detection of anthracycline‐induced cardiomyopathy